ENTITY
Lupin Ltd

Lupin Ltd (LPC IN)

165
Analysis
Health CareIndia
Lupin Limited manufactures bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.
more
bullishLupin Ltd
11 Nov 2024 23:14Broker

LUPIN Ltd - Steady Outlook on Product Development; Maintain ADD

eported revenue grew by 12.6% YoY, led by the India business, which grew by 18.8% YoY, and the Asia-Pacific business, which grew by 30% YoY.

Logo
126 Views
Share
bullishLupin Ltd
05 Nov 2024 06:51Broker

Lupin: US and India on Steady Footing, Upgrade to ADD

We upgrade Lupin (LPC) to ADD from REDUCE with a revised TP of INR 2,440 (31x Q3FY27E, up from INR 1,950 at 28x Q1FY27E)

Logo
167 Views
Share
bullishLupin Ltd
12 Jul 2024 18:57Broker

Lupin - Launches Critical for Sustenance of Turnaround

Lupin’s recent success in US (sales grew ~34% YoY in FY24) is driven by its better regulatory track record and traction in inhalation portfolio.

Share
bullishLupin Ltd
10 May 2024 18:48Broker

Lupin - Niche Product Drives Earnings Growth

Motilal Oswal's research report onLupin Lupin (LPC) delivered in-line operational performance in 4QFY24. LPC ended FY24 on a strong note, with...

Logo
347 Views
Share
bullishLupin Ltd
09 May 2024 21:51Broker

Lupin (LPC IN) - Margins to Sustain

Prabhudas Lilladher's research report onLupin We revise our FY25/26E EPS estimates by 2.1%/4.3%, as we factor in higher margins.

Logo
176 Views
Share
x